Akebia Therapeutics Inc. buy BTIG Research
Start price
29.11.23
/
50%
€0.92
Target price
29.11.24
€3.64
Performance (%)
122.78%
End price
30.11.24
€2.05
Summary
This prediction ended on 30.11.24 with a price of €2.05. With a performance of 122.78% the BUY prediction by BTIG_Research was a big success. BTIG_Research has a follow-up prediction for Akebia Therapeutics Inc. where he still thinks Akebia Therapeutics Inc. is a Buy. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Akebia Therapeutics Inc. | 7.453% | 7.453% | -20.505% |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
In the thread Trading Akebia Therapeutics Inc.
Die von BTIG_Research gewählte maximale Laufzeit wurde überschritten
Current prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.93
29.10.25
29.10.25
€4.29
29.10.26
29.10.26
-28.68%
15.12.25
15.12.25
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.27
02.12.25
02.12.25
€4.31
02.12.26
02.12.26
7.93%
15.12.25
15.12.25